CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 479 filers reported holding CRISPR THERAPEUTICS AG in Q4 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $444,394 | -37.8% | 8,228 | -21.5% | 0.05% | -40.0% |
| Q1 2024 | $714,180 | +9.1% | 10,478 | +0.2% | 0.08% | +2.4% |
| Q4 2023 | $654,358 | +42.7% | 10,453 | +3.5% | 0.08% | +27.7% |
| Q3 2023 | $458,484 | +118.2% | 10,101 | +169.9% | 0.06% | +132.1% |
| Q2 2023 | $210,076 | -39.1% | 3,742 | +21.4% | 0.03% | -36.4% |
| Q3 2021 | $345,000 | -60.0% | 3,082 | -42.1% | 0.04% | -57.7% |
| Q2 2021 | $862,000 | +299.1% | 5,326 | +199.9% | 0.10% | +271.4% |
| Q1 2021 | $216,000 | +237.5% | 1,776 | +30.6% | 0.03% | +250.0% |
| Q2 2019 | $64,000 | – | 1,360 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
| Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
| EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
| NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
| ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
| NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
| Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
| Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |